Onchilles Pharma - About the company
Onchilles Pharma is a series A company based in San Diego (United States), founded in 2017 by Lev Becker and Court R Turner. It operates as a Developer of small molecule therapeutics for cancer. Onchilles Pharma has raised $7M in funding. The company has 3394 active competitors, including 1130 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of small molecule therapeutics for cancer. The company has discovered an anticancer protein neutrophil elastase ELANE released from neutrophils. It activates a pathway of the innate immune system with anti-cancer activity.
- Website
- www.onchillespharma.com/
- Social
- Email ID
- *****@onchillespharma.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2017
Location
San Diego, United States
Stage
Series A
Total Funding
$7M in 1 round
Latest Funding Round
Investors
Ranked
792nd among 3394 active competitors
Employee Count
10 as on Sep 30, 2026
Similar Companies
Sign up to download Onchilles Pharma's company profile
Onchilles Pharma's funding and investors
Onchilles Pharma has raised a total funding of $7M over 1 round. Its latest funding round was a Series A round on Jun 10, 2021 for $*****. 1 investor participated in its latest round. Onchilles Pharma has 2 institutional investors.
Here is the list of recent funding rounds of Onchilles Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 10, 2021 | 2545898 | Series A | 6888288 | 5892942 | 7361945 | 9925262 |
Access funding benchmarks and valuations. Sign up today!View details of Onchilles Pharma's funding rounds and investors
Onchilles Pharma's founders and board of directors
Founder? Claim ProfileThe founders of Onchilles Pharma are Lev Becker and Court R Turner.
Here are the details of Onchilles Pharma's key team members:
- Lev Becker: Co-Founder of Onchilles Pharma and founder of 2 other companies, MA(X) and Rmark Bio.
- Court R Turner: Co-Founder of Onchilles Pharma. Contact Info: 2 email addresses
View details of Onchilles Pharma's Founder profiles and Board Members
Onchilles Pharma's employee count trend
Onchilles Pharma has 10 employees as of Sep 26. Here is Onchilles Pharma's employee count trend over the years:
Uncover Onchilles Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Onchilles Pharma's Competitors and alternates
Top competitors of Onchilles Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Onchilles Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
792nd |  Onchilles Pharma 2017, San Diego (United States), Series A | Developer of small molecule therapeutics for cancer | $7M | 47/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Onchilles Pharma's competitors? Click here to see the top ones
Onchilles Pharma's Investments and acquisitions
Onchilles Pharma has made no investments or acquisitions yet.
Reports related to Onchilles Pharma
Here is the latest report on Onchilles Pharma's sector:
News related to Onchilles Pharma
Filter this listMedia has covered Onchilles Pharma for a total of 7 events in the last 1 year, 5 of them have been about company updates.
•
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid TumorsBusiness Wire•Jun 04, 2026•Onchilles Pharma
•
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate SelectionBusiness Wire•Apr 18, 2026•Onchilles Pharma
•
Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026Business Wire•Mar 17, 2026•Onchilles Pharma
•
Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway into the ClinicBusiness Wire•Feb 02, 2026•Onchilles Pharma
•
Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical AdvisorBusiness Wire•Nov 07, 2025•Onchilles Pharma
•
Onchilles expands team to speed clinical trials for its novel pan-cancer drug.Business Wire•Jan 13, 2025•Onchilles Pharma
•
Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024Business Wire•Nov 07, 2024•Onchilles Pharma
•
Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer TherapeuticBusiness Wire•Nov 03, 2023•Onchilles Pharma
•
Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing ActivityTullahoma News•Apr 19, 2023•Onchilles Pharma
•
Onchilles Pharma Announces Presentation of Preclinical Data for N17350 at AACR 2023ACROFAN•Mar 14, 2023•Onchilles Pharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Onchilles Pharma
Explore our recently published companies
- Creative Ops - United Kingdom based, Unfunded company
- Print3DPro - Unfunded company
- AIZA - Palo Alto based, 2023 founded, Series A company
- Sunandsuncattlefeed - Raipur based, 2017 founded, Unfunded company
- KG Latvija - Sigulda based, 2014 founded, Unfunded company
- Hamyar Site - Unfunded company
